Guggenheim Reiterates Buy on Endo Int'l (ENDP) Following Updated Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Guggenheim Reiterates Buy on Endo Int'l (ENDP) Following Updated Guidance
September 29, 2015 7:42 AM EDT
RBC Capital maintained a Top Pick rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $100.00 (from $107.00), following a guidance update. ENDP pointed to a 3Q range of $720-740 million in revenue which is 4% below consensus at the midpoint.
Analyst... More
September 28, 2015 8:04 AM EDT
ACETO Corp (NASDAQ: ACET) announced that Rising Pharmaceuticals, Inc., its generic finished dosage form subsidiary, has reached agreement to purchase three ANDAs from a subsidiary of Endo International plc (Nasdaq: ENDP) for the products Methimazole Tablets, Glycopyrrolate Tablets and... More
September 28, 2015 6:34 AM EDT
Endo Int'l (NASDAQ: ENDP) announced it has completed its previously announced $8.05 billion acquisition of Par Pharmaceutical Holdings, Inc. from leading global private investment firm TPG.
Through this acquisition, Endo has further established its position as a leading global specialty pharmaceutical company with a fast growing generics business that is among the top five as measured by U.S. sales according to IMS. The acquisition also helps position Endo for long-term double-digit organic growth, enhanced cash flow generation and increased financial flexibility. Endo's generics portfolio now includes an extensive range of in market and... More
